We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Portable Blood-Based Device Detects Colon Cancer

By LabMedica International staff writers
Posted on 14 Mar 2025

Colon cancer is the second leading cause of cancer-related deaths in the U. More...

S., yet it is highly treatable when detected at an early stage. Traditional colonoscopy screenings, although effective, are unpleasant, expensive, and carry the risk of medical complications. Other screening methods, such as stool-based tests, may yield unreliable results and lead to false positives. To address these challenges, researchers are developing a less invasive and portable device that would use blood samples to detect colorectal cancer.

This device, currently being developed by scientists at The University of Texas at El Paso (El Paso, TX, USA), is designed to detect a colon cancer-specific protein called CCSP-2. The presence of CCSP-2 in colon cancer cells is 78 times greater than in normal colon cells, making its detection a strong indicator of the disease. Because CCSP-2 can also be found in the blood, it serves as an excellent biomarker—biological signals that help indicate the presence of specific diseases. The device, an electrochemical immunosensor, is capable of detecting CCSP-2 and is designed to be miniaturized and mass-produced, offering the potential for use in home settings or in doctors' offices.

Before the device can be made available to patients, it will need to be patented and undergo clinical trials, a process that can take several years. The study, published in ACS Measurement Science Au, marks the first in a series of research efforts aimed at evaluating the suitability of various biomarkers for the portable device. This research paves the way for the potential development of a simple, point-of-care portable device for detecting colorectal cancer. In addition, the team is focusing on identifying new proteins that are over-expressed at different stages of colon cancer, which could serve as additional biomarkers for testing on the device.

“The earlier the detection, the greater the hope for saving lives,” said study co-author Ruma Paul. “Blood-based tests are much easier on patients while also being able to precisely detect the early signs of colorectal cancer. Our research could one day make simpler early detection possible.”


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.